APA (7th ed.) Citation

Marmé, F., Aigner, J., Lorenzo Bermejo, J., Sinn, P., Sohn, C., Jäger, D., & Schneeweiss, A. (2013). Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. International journal of cancer, 133(4), . https://doi.org/10.1002/ijc.28094

Chicago Style (17th ed.) Citation

Marmé, Frederik, Julia Aigner, Justo Lorenzo Bermejo, Peter Sinn, Christof Sohn, Dirk Jäger, and Andreas Schneeweiss. "Neoadjuvant Epirubicin, Gemcitabine and Docetaxel for Primary Breast Cancer: Long-term Survival Data and Major Prognostic Factors Based on Two Consecutive Neoadjuvant Phase I/II Trials." International Journal of Cancer 133, no. 4 (2013). https://doi.org/10.1002/ijc.28094.

MLA (9th ed.) Citation

Marmé, Frederik, et al. "Neoadjuvant Epirubicin, Gemcitabine and Docetaxel for Primary Breast Cancer: Long-term Survival Data and Major Prognostic Factors Based on Two Consecutive Neoadjuvant Phase I/II Trials." International Journal of Cancer, vol. 133, no. 4, 2013, https://doi.org/10.1002/ijc.28094.